VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the closing of its underwritten public offering of 3,809,524 shares, raising approximately $20 million before expenses. All shares were sold by Volition, and the underwriter has an option to purchase an additional 571,428 shares. The funds will be used for general corporate purposes, including product development and potential acquisitions. The offering was conducted under a previously filed shelf registration statement with the SEC.

Positive

• Raised approximately $20 million through the public offering.
• Funds intended for product development and potential strategic acquisitions.

Negative

• Dilution risk due to the issuance of new shares.

AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its underwritten public offering of 3,809,524 shares of its common stock (the "Offering") for gross proceeds of approximately $20 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares in the Offering were sold by Volition. In addition, Volition has granted the underwriter for the Offering a 30-day option to purchase up to an additional 571,428 shares of its common stock.

Cantor Fitzgerald & Co. acted as the sole book running manager of the Offering.

Volition intends to use the net proceeds of the Offering for general corporate purposes, which may include continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.

The Offering was made pursuant to a "shelf" registration statement on Form S-3 (File No. 333-227248) previously filed by Volition with the Securities and Exchange Commission (the "SEC") on September 26, 2018 and declared effective by the SEC on September 28, 2018. The Offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The final prospectus supplement relating to and describing the terms of the Offering was filed with the SEC on February 11, 2021 and is available on the SEC's website at www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to the Offering may also be obtained by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Volition

Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic products to market.

Media / Investor Contacts

Louise Batchelor, Volition
mediarelations@volition.com 
+44 (0)7557 774620

Scott Powell, Volition
investorrelations@volition.com 
+1 (646) 650 1351

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements, and include statements regarding the Offering. These forward-looking statements are based upon current estimates and assumptions and include statements regarding Volition's intended use of proceeds from the Offering. Volition's actual results may differ materially from current expectations and assumptions from those indicated or implied by any forward-looking statements due to numerous risks and uncertainties. Risks and uncertainties include, without limitation, Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the SEC. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ is a trademark and/or service mark of VolitionRx Limited and its subsidiaries.

View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-announces-closing-of-20-million-underwritten-public-offering-of-common-stock-301227626.html

SOURCE VolitionRx Ltd

FAQ

What is the amount raised in the VNRX public offering?

VolitionRx raised approximately $20 million through its recent public offering.

What will VolitionRx do with the proceeds from the offering?

The proceeds will be used for general corporate purposes, including product development and potential acquisitions.

How many shares were sold in the VNRX offering?

A total of 3,809,524 shares of common stock were sold in the offering.

Is there an option for additional shares in VNRX's offering?

Yes, the underwriter has a 30-day option to purchase up to an additional 571,428 shares.

What was the registration status of VNRX's offering?

The offering was made pursuant to an effective shelf registration statement filed with the SEC.